Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–63. https://doi.org/10.3322/caac.21834.

Article  PubMed  Google Scholar 

Eslami M, Memarsadeghi O, Davarpanah A, Arti A, Nayernia K, Behnam B. Overcoming chemotherapy resistance in metastatic cancer: a comprehensive review. Biomedicines. 2024;12:183. https://doi.org/10.3390/biomedicines12010183.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zugazagoitia J, Guedes C, Ponce S, Ferrer I, Molina-Pinelo S, Paz-Ares L. Current challenges in cancer treatment. Clin Ther. 2016;38:1551–66. https://doi.org/10.1016/j.clinthera.2016.03.026.

Article  PubMed  Google Scholar 

Zhao Z, Shilatifard A. Epigenetic modifications of histones in cancer. Genome Biol. 2019;20:1–16. https://doi.org/10.1186/s13059-019-1870-5.

Article  Google Scholar 

Tao L, Zhou Y, Luo Y, Qiu J, Xiao Y, Zou J, et al. Epigenetic regulation in cancer therapy: From mechanisms to clinical advances. MedComm–Oncology. 2024;3:e59. https://doi.org/10.1002/mog2.59.

Article  CAS  Google Scholar 

Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol. 2007;1:19–25. https://doi.org/10.1016/j.molonc.2007.01.001.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Raouf YS. Targeting histone deacetylases: emerging applications beyond cancer. Drug Discov Today. 2024;29:104094. https://doi.org/10.1016/j.drudis.2024.104094.

Article  CAS  PubMed  Google Scholar 

Marmorstein R, Roth SY. Histone acetyltransferases: function, structure, and catalysis. Curr Opini Genet Dev. 2001;11:155–61. https://doi.org/10.1016/s0959-437x(00)00173-8.

Article  CAS  Google Scholar 

Carew JS, Giles FJ, Nawrocki ST. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett. 2008;269:7–17. https://doi.org/10.1016/j.canlet.2008.03.037.

Article  CAS  PubMed  Google Scholar 

Ramaiah MJ, Tangutur AD, Manyam RR. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy. Life Sci. 2021;277:119504. https://doi.org/10.1016/j.lfs.2021.119504.

Article  CAS  PubMed  Google Scholar 

Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5:769–84. https://doi.org/10.1038/nrd2133.

Article  CAS  PubMed  Google Scholar 

Wael AAF, Mohamed FEA, Nemr MTM, Sayed AM, Khalil RG, Zidan TH. Novel benzenesulfonamide derivatives as potential selective carbonic anhydrase IX, XII inhibitors with anti-proliferative activity: design, synthesis and in silico studies. Bioorg Chem. 2024;153:107881. https://doi.org/10.1016/j.bioorg.2024.107881.

Article  CAS  Google Scholar 

Aboelez MO, El-Remaily MAEAAA, Kamel MS, Al KO, Fadaly WAA, et al. Novel 3,4-diaminothieno[2,3-b]thiophene-2,5-dicarbohydrazide-based scaffolds as EGFRWT, EGFRT790M, and tubulin polymerization inhibitors with anti-proliferative activity. Bioorg Chem. 2024;163:108728. https://doi.org/10.1016/j.bioorg.2025.108728.

Article  CAS  Google Scholar 

Mohamed MFA, Salem IM, Fouad A, Allam RM, Fadaly WAA, Nemr MTM, et al. Synthesis and apoptotic induction of sulfonamide-based chalcone hybrids as first-in-class dual histone deacetylase-carbonic anhydrase inhibitors with potential anti-tubulin activity. Bioorg Chem. 2025;163:108694. https://doi.org/10.1016/j.bioorg.2025.108694.

Article  CAS  PubMed  Google Scholar 

Banerjee S, Adhikari N, Amin SA, Jha T. Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: an overview. Eur J Med Chem. 2006;164:214–40. https://doi.org/10.1016/j.ejmech.2018.12.039.

Article  CAS  Google Scholar 

Micelli C, Rastelli G. Histone deacetylases: structural determinants of inhibitor selectivity. Drug Discov Today. 2015;20:718–35. https://doi.org/10.1016/j.drudis.2015.01.007.

Article  CAS  PubMed  Google Scholar 

Roche J, Bertrand P. Inside HDACs with more selective HDAC inhibitors. Eur J Med Chem. 2016;121:451–83. https://doi.org/10.1016/j.ejmech.2016.05.047.

Article  CAS  PubMed  Google Scholar 

Saunders LR, Verdin E. Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene. 2016;26:5489–504. https://doi.org/10.1016/j.ejmech.2016.05.047.

Article  CAS  Google Scholar 

Ha VT, Kien VT, Tien VD, My NTT, Nam NH, Baltas M, et al. Design, synthesis and biological evaluation of novel hydroxamic acids bearing artemisinin skeleton. Bioorg Chem. 2016;66:63–71. https://doi.org/10.1016/j.bioorg.2016.03.008.

Article  CAS  PubMed  Google Scholar 

Giannini G, Cabri W, Fattorusso C, Rodriquez M. Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives. Future Med Chem. 2012;4:1439–60. https://doi.org/10.4155/fmc.12.80.

Article  CAS  PubMed  Google Scholar 

De Souza C, Chatterji BP. HDAC inhibitors as novel anti-cancer therapeutics. Recent Pat Anticancer Drug Discov. 2015;10:145–62. https://doi.org/10.2174/1574892810666150317144511.

Article  CAS  PubMed  Google Scholar 

Sun P, Wang J, Khan KS, Yang W, Ng BWL, Ilment N, et al. Development of alkylated hydrazides as highly potent and selective class I histone deacetylase inhibitors with T cell modulatory properties. J Med Chem. 2022;65:16313–37. https://doi.org/10.1021/acs.jmedchem.2c01132.

Article  CAS  PubMed  Google Scholar 

Sangwan R, Rajan R, Mandal PK. HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors. Eur J Med Chem. 2018;158:620–706. https://doi.org/10.1016/j.ejmech.2018.08.073.

Article  CAS  PubMed  Google Scholar 

Huong TTL, Dung PTP, Huong PT, Vu TK, Hahn H, Han BW, et al. Novel 2-oxoindoline-based hydroxamic acids: synthesis, cytotoxicity, and inhibition of histone deacetylation. Tetrahedron Lett. 2015;56:6425–9. https://doi.org/10.1016/j.tetlet.2015.09.147.

Article  CAS  Google Scholar 

Liu T, Wan Y, Xiao Y, Xia C, Duan G. Dual-target inhibitors based on HDACs: novel antitumor agents for cancer therapy. J Med Chem. 2020;63:8977–9002. https://doi.org/10.1021/acs.jmedchem.0c00491.

Article  CAS  PubMed  Google Scholar 

Gupta D, Guliani E, Bajaj K. Coumarin—synthetic methodologies, pharmacology, and application as natural fluorophore. Top Curr Chem (Cham). 2024;382:16. https://doi.org/10.1007/s41061-024-00462-z.

Article  CAS  PubMed  Google Scholar 

Bouhaoui A, Eddahmi M, Dib M, Khouili M, Aires A, Catto M, et al. Synthesis and biological properties of coumarin derivatives. a review. ChemistrySelect. 2021;6:5848–70. https://doi.org/10.1002/slct.202101346.

Article  CAS  Google Scholar 

Yadav AK, Shrestha RM, Yadav PN. Anticancer mechanism of coumarin-based derivatives. Eur J Med Chem. 2024;267:116179. https://doi.org/10.1016/j.ejmech.2024.116179.

Article  CAS  PubMed  Google Scholar 

Rawat A, Reddy AVB. Recent advances on anticancer activity of coumarin derivatives. Eur J Med Chem Rep. 2022;5:100038. https://doi.org/10.1016/j.ejmcr.2022.100038.

Article  CAS  Google Scholar 

Koley M, Han J, Soloshonok VA, MoJumder S, Javahershenas R, Makarem A. Latest developments in coumarin-based anticancer agents: mechanism of action and structure–activity relationship studies. RSC Med Chem. 2023;15:10–54. https://doi.org/10.1039/d3md00511a.

Article